TriangleDISEASE & TREATMENT SETTING
recurrent Laryngeal Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Metastatic and Recurrent Laryngeal Cancer
Broader topic: Laryngeal Cancer
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- prior therapy
- status
- stated
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Metastatic and Recurrent Laryngeal Cancer
Study evidence for this setting
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice